

ASX/Media Release

23 November 2020

Results of Annual General Meeting

Perth 23 November 2020: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that the Annual General Meeting of the Company was held today, 23 November 2020. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Adoption of Remuneration Report (non-binding)	87,613,592	7,198,808	17,404,658
2	Re-election of Director –Mr Matthew Callahan	182,192,072	598,210	165,083
3	Approval of Additional 10% Placement Capacity	175,666,367	6,120,822	1,169,176

Summary of Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report (non-binding)	82,148,478	7,198,808	1,725,114	16,572,241
2	Re-election of Director –Mr Matthew Callahan	175,887,941	598,210	1,731,714	165,083
3	Approval of Additional 10% Placement Capacity	169,231,415	6,120,822	1,861,535	1,169,176

Release authorised by

Simon Robertson

Company Secretary

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage synthetic cannabinoid company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate cannabinoid development platforms, dermatology and antimicrobial

products, both of which leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases.

The Company is developing a pipeline of product candidates that leverages the antimicrobial properties of cannabinoids, with the BTX 1801 Phase 2a study for the prevention of surgical site infections fully enrolled. For the dermatology platform, the Company has confirmed a drug development plan for the BTX 1503 acne program to support registration and plans to progress its Phase 2b rosacea study in the near future.

To learn more please visit: <https://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

botanixpharma@vesparum.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.